Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane

Spiliotaki, Maria; Kallergi, Galatea; Nikolaou, Christos; Xenidis, Nikolaos; Politaki, Eleni; Apostolaki, Stella; Georgoulia, Nefeli; Koinis, Filippos; Tsoukalas, Nikolaos; Hatzidaki, Dora; Κotsakis, Athanasios; Georgoulias, Vassilis

doi:10.1007/s00280-020-04227-5

Cited by 5 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, a study conducted by De Luca et al, carried out in a patient with breast cancer, observed that most of the CTC mutations that were detected at the beginning of the study disappeared during treatment, while new mutations emerged [ 71 ]. Furthermore, the study of CTCs has already been shown to be useful for deciphering resistance mechanisms in luminal patients treated with endocrine therapy [ 72 , 73 ].…”

Section: Circulating Tumour Cell (Ctc) Analysis As a Novel Biomarker For Managing Hr+/her2− Mbc Patientsmentioning

confidence: 99%

Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer

González-Conde

Yáñez-Gómez

López‐López

et al. 2021

JPM

View full text Add to dashboard Cite

Breast cancer (BC) is the most common cancer diagnosed in women worldwide. Approximately 70% of BC patients have the luminal subtype, which expresses hormone receptors (HR+). Adjuvant endocrine treatments are the standard of care for HR+/HER2− BC patients. Over time, approximately 30% of those patients develop endocrine resistance and metastatic disease. Cyclin-dependent kinase inhibitors (CDKi), in combination with an aromatase inhibitor or fulvestrant, have demonstrated superior efficacies in increasing progression-free survival, with a safe toxicity profile, in HR+/HER2− metastatic BC patients. CDKi blocks kinases 4/6, preventing G1/S cell cycle transition. However, not all of the patients respond to CDKi, and those who do respond ultimately develop resistance to the combined therapy. Studies in tumour tissues and cell lines have tried to elucidate the mechanisms that underlie this progression, but there are still no conclusive data. Over the last few years, liquid biopsy has contributed relevant information. Circulating tumour materials are potential prognostic markers for determining patient prognosis in metastatic luminal BC, for monitoring disease, and for treatment selection. This review outlines the different studies performed using liquid biopsy in patients with HR+ metastatic BC treated with CDKi plus endocrine therapy. We mainly focus on those studies that describe the possible resistance mechanisms in circulating tumour-derived material.

show abstract

Section: Circulating Tumour Cell (Ctc) Analysis As a Novel Biomarker For Managing Hr+/her2− Mbc Patientsmentioning

confidence: 99%

Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer

González-Conde

Yáñez-Gómez

López‐López

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…CTCs have been shown to act as a driving force of cancer initiation and progression, contributing to resistance to treatment [ 10 ]. Moreover, a clear-cut correlation between the absolute number of CTCs in the peripheral blood and the clinical outcome of patients with various tumor types has also been confirmed [ 11 , 12 , 13 ]. These findings account for the interest in the potential impact of CTCs on the clinical outcome of patients with PCa.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study

Koinis,

Zafeiriou,

Messaritakis

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Rational: Circulating tumor cells (CTCs) appear to be a promising tool for predicting the clinical outcome and monitoring the response to treatment in patients with solid tumors. The current study assessed the clinical relevance of monitoring CTCs in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel. Patients and Methods: Patients with histologically confirmed mCRPC who were previously treated with a docetaxel-containing regimen and experienced disease progression were enrolled in this multicenter prospective study. CTC counts were enumerated using the CellSearch system at baseline (before cabazitaxel initiation), after one cabazitaxel cycle (post 1st cycle) and at disease progression (PD). Patients were stratified into predetermined CTC-positive and CTC-negative groups. The phenotypic characterization was performed using double immunofluorescence staining with anti-CKs and anti-Ki67, anti-M30 or anti-vimentin antibodies. Results: The median PFS and OS were 4.0 (range, 1.0–17.9) and 14.5 (range, 1.2–33.9) months, respectively. At baseline, 48 out of 57 (84.2%) patients had ≥1 CTCs/7.5 mL of peripheral blood (PB) and 37 (64.9%) had ≥5 CTCs/7.5 mL of PB. After one treatment cycle, 30 (75%) out of the 40 patients with available measurements had ≥1 detectable CTC/7.5 mL of PB and 24 (60%) ≥ 5CTCs/7.5 mL of PB; 12.5% of the patients with detectable CTCs at the baseline sample had no detectable CTCs after one treatment cycle. The detection of ≥5CTCs/7.5 mL of PB at baseline and post-cycle 1 was associated with shorter PFS and OS (p = 0.002), whereas a positive CTC status post-cycle 1 strongly correlated with poorer OS irrespective of the CTC cut-off used. Multivariate analysis revealed that the detection of non-apoptotic (CK+/M30−) CTCs at baseline is an independent predictor of shorter OS (p = 0.005). Conclusions: In patients with mCRPC treated with cabazitaxel, CTC counts both at baseline and after the first cycle retain their prognostic significance, implying that liquid biopsy monitoring might serve as a valuable tool for predicting treatment efficacy and survival outcomes.

show abstract

Mathematical Oncology to Integrate Multimodal Clinical and Liquid Biopsy Data for the Prediction of Survival

Ndacayisaba

Mason

Kühn

2023

Circulating Tumor Cells

View full text Add to dashboard Cite

Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane

Cited by 5 publications

References 42 publications

Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer

Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer

Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study

Mathematical Oncology to Integrate Multimodal Clinical and Liquid Biopsy Data for the Prediction of Survival

Contact Info

Product

Resources

About